Congress Presentations
Stay informed about the latest scientific and medical research from Axsome.
American Academy of Neurology (AAN) 2026
Chicago, IL | April 18 - 22, 2026
AXS-12 | Narcolepsy
Impact of AXS-12 on Symptom Severity and Functional Impairment in Narcolepsy: Results from the Phase 3 SYMPHONY Trial
AXS-12 | Narcolepsy
ENCORE: Topline Results of a Phase 3 Open-label Extension and Randomized-Withdrawal Study of AXS-12 in Narcolepsy
AXS-12 | Narcolepsy
Residual Symptom Burden in Patients With Narcolepsy Satisfied With Treatment: Subgroup Analysis From the CRESCENDO Survey
Solriamfetol | Excessive Daytime Sleepiness
Effects of Solriamfetol on Neuropsychological Outcomes in Patients With Obstructive Sleep Apnea in the Real-World SURWEY Study
Symbravo® | Migraine
Efficacy and Safety of Symbravo® (MoSEICTM meloxicam and rizatriptan) in Participants With Migraine Experiencing an Inadequate Response to Oral CGRP Inhibitors: Topline Results From the EMERGE Study
Symbravo® | Migraine
Long-Term Effects of Symbravo® (MoSEICTM Meloxicam and Rizatriptan) on Headache Burden and Quality of Life: Results of the MOVEMENT Trial
Symbravo® | Migraine
Efficacy of Symbravo® (MoSEICTM Meloxicam and Rizatriptan) by Baseline Migraine-Associated Disability: Post-hoc Analysis of the INTERCEPT Trial
